0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Anti-VEGF Intravitreal Drugs Market Research Report 2024
Published Date: August 2024
|
Report Code: QYRE-Auto-7B18191
Home | Market Reports | Health| Pharmacy| Drugs & Medications
Global Anti VEGF Intravitreal Drugs Market Research Report 2024
BUY CHAPTERS

Global Anti-VEGF Intravitreal Drugs Market Research Report 2024

Code: QYRE-Auto-7B18191
Report
August 2024
Pages:87
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Anti-VEGF Intravitreal Drugs Market

Anti-VEGF intravitreal drugs refer to a class of medications used in ophthalmology to treat various eye conditions characterized by abnormal blood vessel growth and leakage,notably wet age-related macular degeneration(AMD),diabetic retinopathy,and macular edema,which work by blocking VEGF.These medications help reduce the growth of abnormal blood vessels,decrease vascular leakage, and thereby stabilize or improve vision.
The global Anti-VEGF Intravitreal Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Anti-VEGF Intravitreal Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Anti-VEGF Intravitreal Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Anti-VEGF Intravitreal Drugs include Roche, Novartis, Biogen, Coherus BioSciences, Regeneron Pharmaceuticals, Samsung Bioepis, Biocon Biologics, Qilu Pharma, Chengdu Kanghong Pharmaceutical, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Anti-VEGF Intravitreal Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-VEGF Intravitreal Drugs.
The Anti-VEGF Intravitreal Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Dose) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Anti-VEGF Intravitreal Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anti-VEGF Intravitreal Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Anti-VEGF Intravitreal Drugs Market Report

Report Metric Details
Report Name Anti-VEGF Intravitreal Drugs Market
Segment by Type
Segment by Application
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Roche, Novartis, Biogen, Coherus BioSciences, Regeneron Pharmaceuticals, Samsung Bioepis, Biocon Biologics, Qilu Pharma, Chengdu Kanghong Pharmaceutical
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Anti-VEGF Intravitreal Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Anti-VEGF Intravitreal Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Anti-VEGF Intravitreal Drugs Market report?

Ans: The main players in the Anti-VEGF Intravitreal Drugs Market are Roche, Novartis, Biogen, Coherus BioSciences, Regeneron Pharmaceuticals, Samsung Bioepis, Biocon Biologics, Qilu Pharma, Chengdu Kanghong Pharmaceutical

What are the Application segmentation covered in the Anti-VEGF Intravitreal Drugs Market report?

Ans: The Applications covered in the Anti-VEGF Intravitreal Drugs Market report are Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Other

What are the Type segmentation covered in the Anti-VEGF Intravitreal Drugs Market report?

Ans: The Types covered in the Anti-VEGF Intravitreal Drugs Market report are Ranibizumab, Aflibercept, Conbercept, Brolucizumab, Faricimab, Other

Recommended Reports

Ophthalmic Drug Markets

Retinal Disorder Treatments

VEGF & Anti-VEGF Drugs

1 Anti-VEGF Intravitreal Drugs Market Overview
1.1 Product Definition
1.2 Anti-VEGF Intravitreal Drugs by Type
1.2.1 Global Anti-VEGF Intravitreal Drugs Market Value Comparison by Type (2024-2030)
1.2.2 Ranibizumab
1.2.3 Aflibercept
1.2.4 Conbercept
1.2.5 Brolucizumab
1.2.6 Faricimab
1.2.7 Other
1.3 Anti-VEGF Intravitreal Drugs by Application
1.3.1 Global Anti-VEGF Intravitreal Drugs Market Value by Application (2024-2030)
1.3.2 Age-related Macular Degeneration
1.3.3 Diabetic Macular Edema
1.3.4 Retinal Vein Occlusion
1.3.5 Other
1.4 Global Anti-VEGF Intravitreal Drugs Market Size Estimates and Forecasts
1.4.1 Global Anti-VEGF Intravitreal Drugs Revenue 2019-2030
1.4.2 Global Anti-VEGF Intravitreal Drugs Sales 2019-2030
1.4.3 Global Anti-VEGF Intravitreal Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Anti-VEGF Intravitreal Drugs Market Competition by Manufacturers
2.1 Global Anti-VEGF Intravitreal Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Anti-VEGF Intravitreal Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of Anti-VEGF Intravitreal Drugs, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Anti-VEGF Intravitreal Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Anti-VEGF Intravitreal Drugs, Product Type & Application
2.7 Global Key Manufacturers of Anti-VEGF Intravitreal Drugs, Date of Enter into This Industry
2.8 Global Anti-VEGF Intravitreal Drugs Market Competitive Situation and Trends
2.8.1 Global Anti-VEGF Intravitreal Drugs Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Anti-VEGF Intravitreal Drugs Players Market Share by Revenue
2.8.3 Global Anti-VEGF Intravitreal Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Anti-VEGF Intravitreal Drugs Market Scenario by Region
3.1 Global Anti-VEGF Intravitreal Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Anti-VEGF Intravitreal Drugs Sales by Region: 2019-2030
3.2.1 Global Anti-VEGF Intravitreal Drugs Sales by Region: 2019-2024
3.2.2 Global Anti-VEGF Intravitreal Drugs Sales by Region: 2025-2030
3.3 Global Anti-VEGF Intravitreal Drugs Revenue by Region: 2019-2030
3.3.1 Global Anti-VEGF Intravitreal Drugs Revenue by Region: 2019-2024
3.3.2 Global Anti-VEGF Intravitreal Drugs Revenue by Region: 2025-2030
3.4 North America Anti-VEGF Intravitreal Drugs Market Facts & Figures by Country
3.4.1 North America Anti-VEGF Intravitreal Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Anti-VEGF Intravitreal Drugs Sales by Country (2019-2030)
3.4.3 North America Anti-VEGF Intravitreal Drugs Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Anti-VEGF Intravitreal Drugs Market Facts & Figures by Country
3.5.1 Europe Anti-VEGF Intravitreal Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Anti-VEGF Intravitreal Drugs Sales by Country (2019-2030)
3.5.3 Europe Anti-VEGF Intravitreal Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Anti-VEGF Intravitreal Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Anti-VEGF Intravitreal Drugs Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Anti-VEGF Intravitreal Drugs Sales by Region (2019-2030)
3.6.3 Asia Pacific Anti-VEGF Intravitreal Drugs Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Anti-VEGF Intravitreal Drugs Market Facts & Figures by Country
3.7.1 Latin America Anti-VEGF Intravitreal Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Anti-VEGF Intravitreal Drugs Sales by Country (2019-2030)
3.7.3 Latin America Anti-VEGF Intravitreal Drugs Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Anti-VEGF Intravitreal Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Anti-VEGF Intravitreal Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Anti-VEGF Intravitreal Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Anti-VEGF Intravitreal Drugs Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Anti-VEGF Intravitreal Drugs Sales by Type (2019-2030)
4.1.1 Global Anti-VEGF Intravitreal Drugs Sales by Type (2019-2024)
4.1.2 Global Anti-VEGF Intravitreal Drugs Sales by Type (2025-2030)
4.1.3 Global Anti-VEGF Intravitreal Drugs Sales Market Share by Type (2019-2030)
4.2 Global Anti-VEGF Intravitreal Drugs Revenue by Type (2019-2030)
4.2.1 Global Anti-VEGF Intravitreal Drugs Revenue by Type (2019-2024)
4.2.2 Global Anti-VEGF Intravitreal Drugs Revenue by Type (2025-2030)
4.2.3 Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Anti-VEGF Intravitreal Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Anti-VEGF Intravitreal Drugs Sales by Application (2019-2030)
5.1.1 Global Anti-VEGF Intravitreal Drugs Sales by Application (2019-2024)
5.1.2 Global Anti-VEGF Intravitreal Drugs Sales by Application (2025-2030)
5.1.3 Global Anti-VEGF Intravitreal Drugs Sales Market Share by Application (2019-2030)
5.2 Global Anti-VEGF Intravitreal Drugs Revenue by Application (2019-2030)
5.2.1 Global Anti-VEGF Intravitreal Drugs Revenue by Application (2019-2024)
5.2.2 Global Anti-VEGF Intravitreal Drugs Revenue by Application (2025-2030)
5.2.3 Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Application (2019-2030)
5.3 Global Anti-VEGF Intravitreal Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Roche
6.1.1 Roche Company Information
6.1.2 Roche Description and Business Overview
6.1.3 Roche Anti-VEGF Intravitreal Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Roche Anti-VEGF Intravitreal Drugs Product Portfolio
6.1.5 Roche Recent Developments/Updates
6.2 Novartis
6.2.1 Novartis Company Information
6.2.2 Novartis Description and Business Overview
6.2.3 Novartis Anti-VEGF Intravitreal Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Novartis Anti-VEGF Intravitreal Drugs Product Portfolio
6.2.5 Novartis Recent Developments/Updates
6.3 Biogen
6.3.1 Biogen Company Information
6.3.2 Biogen Description and Business Overview
6.3.3 Biogen Anti-VEGF Intravitreal Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Biogen Anti-VEGF Intravitreal Drugs Product Portfolio
6.3.5 Biogen Recent Developments/Updates
6.4 Coherus BioSciences
6.4.1 Coherus BioSciences Company Information
6.4.2 Coherus BioSciences Description and Business Overview
6.4.3 Coherus BioSciences Anti-VEGF Intravitreal Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Coherus BioSciences Anti-VEGF Intravitreal Drugs Product Portfolio
6.4.5 Coherus BioSciences Recent Developments/Updates
6.5 Regeneron Pharmaceuticals
6.5.1 Regeneron Pharmaceuticals Company Information
6.5.2 Regeneron Pharmaceuticals Description and Business Overview
6.5.3 Regeneron Pharmaceuticals Anti-VEGF Intravitreal Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Regeneron Pharmaceuticals Anti-VEGF Intravitreal Drugs Product Portfolio
6.5.5 Regeneron Pharmaceuticals Recent Developments/Updates
6.6 Samsung Bioepis
6.6.1 Samsung Bioepis Company Information
6.6.2 Samsung Bioepis Description and Business Overview
6.6.3 Samsung Bioepis Anti-VEGF Intravitreal Drugs Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Samsung Bioepis Anti-VEGF Intravitreal Drugs Product Portfolio
6.6.5 Samsung Bioepis Recent Developments/Updates
6.7 Biocon Biologics
6.7.1 Biocon Biologics Company Information
6.7.2 Biocon Biologics Description and Business Overview
6.7.3 Biocon Biologics Anti-VEGF Intravitreal Drugs Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Biocon Biologics Anti-VEGF Intravitreal Drugs Product Portfolio
6.7.5 Biocon Biologics Recent Developments/Updates
6.8 Qilu Pharma
6.8.1 Qilu Pharma Company Information
6.8.2 Qilu Pharma Description and Business Overview
6.8.3 Qilu Pharma Anti-VEGF Intravitreal Drugs Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Qilu Pharma Anti-VEGF Intravitreal Drugs Product Portfolio
6.8.5 Qilu Pharma Recent Developments/Updates
6.9 Chengdu Kanghong Pharmaceutical
6.9.1 Chengdu Kanghong Pharmaceutical Company Information
6.9.2 Chengdu Kanghong Pharmaceutical Description and Business Overview
6.9.3 Chengdu Kanghong Pharmaceutical Anti-VEGF Intravitreal Drugs Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Chengdu Kanghong Pharmaceutical Anti-VEGF Intravitreal Drugs Product Portfolio
6.9.5 Chengdu Kanghong Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Anti-VEGF Intravitreal Drugs Industry Chain Analysis
7.2 Anti-VEGF Intravitreal Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Anti-VEGF Intravitreal Drugs Production Mode & Process
7.4 Anti-VEGF Intravitreal Drugs Sales and Marketing
7.4.1 Anti-VEGF Intravitreal Drugs Sales Channels
7.4.2 Anti-VEGF Intravitreal Drugs Distributors
7.5 Anti-VEGF Intravitreal Drugs Customers
8 Anti-VEGF Intravitreal Drugs Market Dynamics
8.1 Anti-VEGF Intravitreal Drugs Industry Trends
8.2 Anti-VEGF Intravitreal Drugs Market Drivers
8.3 Anti-VEGF Intravitreal Drugs Market Challenges
8.4 Anti-VEGF Intravitreal Drugs Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Anti-VEGF Intravitreal Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)
 Table 2. Global Anti-VEGF Intravitreal Drugs Market Value by Application (2024-2030) & (US$ Million)
 Table 3. Global Anti-VEGF Intravitreal Drugs Market Competitive Situation by Manufacturers in 2023
 Table 4. Global Anti-VEGF Intravitreal Drugs Sales (K Dose) of Key Manufacturers (2019-2024)
 Table 5. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Manufacturers (2019-2024)
 Table 6. Global Anti-VEGF Intravitreal Drugs Revenue (US$ Million) by Manufacturers (2019-2024)
 Table 7. Global Anti-VEGF Intravitreal Drugs Revenue Share by Manufacturers (2019-2024)
 Table 8. Global Market Anti-VEGF Intravitreal Drugs Average Price (US$/Dose) of Key Manufacturers (2019-2024)
 Table 9. Global Key Players of Anti-VEGF Intravitreal Drugs, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Anti-VEGF Intravitreal Drugs, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Anti-VEGF Intravitreal Drugs, Product Type & Application
 Table 12. Global Key Manufacturers of Anti-VEGF Intravitreal Drugs, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Anti-VEGF Intravitreal Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-VEGF Intravitreal Drugs as of 2023)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Anti-VEGF Intravitreal Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Table 17. Global Anti-VEGF Intravitreal Drugs Sales by Region (2019-2024) & (K Dose)
 Table 18. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Region (2019-2024)
 Table 19. Global Anti-VEGF Intravitreal Drugs Sales by Region (2025-2030) & (K Dose)
 Table 20. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Region (2025-2030)
 Table 21. Global Anti-VEGF Intravitreal Drugs Revenue by Region (2019-2024) & (US$ Million)
 Table 22. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Region (2019-2024)
 Table 23. Global Anti-VEGF Intravitreal Drugs Revenue by Region (2025-2030) & (US$ Million)
 Table 24. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Region (2025-2030)
 Table 25. North America Anti-VEGF Intravitreal Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 26. North America Anti-VEGF Intravitreal Drugs Sales by Country (2019-2024) & (K Dose)
 Table 27. North America Anti-VEGF Intravitreal Drugs Sales by Country (2025-2030) & (K Dose)
 Table 28. North America Anti-VEGF Intravitreal Drugs Revenue by Country (2019-2024) & (US$ Million)
 Table 29. North America Anti-VEGF Intravitreal Drugs Revenue by Country (2025-2030) & (US$ Million)
 Table 30. Europe Anti-VEGF Intravitreal Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 31. Europe Anti-VEGF Intravitreal Drugs Sales by Country (2019-2024) & (K Dose)
 Table 32. Europe Anti-VEGF Intravitreal Drugs Sales by Country (2025-2030) & (K Dose)
 Table 33. Europe Anti-VEGF Intravitreal Drugs Revenue by Country (2019-2024) & (US$ Million)
 Table 34. Europe Anti-VEGF Intravitreal Drugs Revenue by Country (2025-2030) & (US$ Million)
 Table 35. Asia Pacific Anti-VEGF Intravitreal Drugs Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
 Table 36. Asia Pacific Anti-VEGF Intravitreal Drugs Sales by Region (2019-2024) & (K Dose)
 Table 37. Asia Pacific Anti-VEGF Intravitreal Drugs Sales by Region (2025-2030) & (K Dose)
 Table 38. Asia Pacific Anti-VEGF Intravitreal Drugs Revenue by Region (2019-2024) & (US$ Million)
 Table 39. Asia Pacific Anti-VEGF Intravitreal Drugs Revenue by Region (2025-2030) & (US$ Million)
 Table 40. Latin America Anti-VEGF Intravitreal Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 41. Latin America Anti-VEGF Intravitreal Drugs Sales by Country (2019-2024) & (K Dose)
 Table 42. Latin America Anti-VEGF Intravitreal Drugs Sales by Country (2025-2030) & (K Dose)
 Table 43. Latin America Anti-VEGF Intravitreal Drugs Revenue by Country (2019-2024) & (US$ Million)
 Table 44. Latin America Anti-VEGF Intravitreal Drugs Revenue Market Share by Country (2019-2024)
 Table 45. Middle East and Africa Anti-VEGF Intravitreal Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 46. Middle East and Africa Anti-VEGF Intravitreal Drugs Sales by Country (2019-2024) & (K Dose)
 Table 47. Middle East and Africa Anti-VEGF Intravitreal Drugs Sales by Country (2025-2030) & (K Dose)
 Table 48. Middle East and Africa Anti-VEGF Intravitreal Drugs Revenue by Country (2019-2024) & (US$ Million)
 Table 49. Middle East and Africa Anti-VEGF Intravitreal Drugs Revenue by Country (2025-2030) & (US$ Million)
 Table 50. Global Anti-VEGF Intravitreal Drugs Sales (K Dose) by Type (2019-2024)
 Table 51. Global Anti-VEGF Intravitreal Drugs Sales (K Dose) by Type (2025-2030)
 Table 52. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Type (2019-2024)
 Table 53. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Type (2025-2030)
 Table 54. Global Anti-VEGF Intravitreal Drugs Revenue (US$ Million) by Type (2019-2024)
 Table 55. Global Anti-VEGF Intravitreal Drugs Revenue (US$ Million) by Type (2025-2030)
 Table 56. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Type (2019-2024)
 Table 57. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Type (2025-2030)
 Table 58. Global Anti-VEGF Intravitreal Drugs Price (US$/Dose) by Type (2019-2024)
 Table 59. Global Anti-VEGF Intravitreal Drugs Price (US$/Dose) by Type (2025-2030)
 Table 60. Global Anti-VEGF Intravitreal Drugs Sales (K Dose) by Application (2019-2024)
 Table 61. Global Anti-VEGF Intravitreal Drugs Sales (K Dose) by Application (2025-2030)
 Table 62. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Application (2019-2024)
 Table 63. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Application (2025-2030)
 Table 64. Global Anti-VEGF Intravitreal Drugs Revenue (US$ Million) by Application (2019-2024)
 Table 65. Global Anti-VEGF Intravitreal Drugs Revenue (US$ Million) by Application (2025-2030)
 Table 66. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Application (2019-2024)
 Table 67. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Application (2025-2030)
 Table 68. Global Anti-VEGF Intravitreal Drugs Price (US$/Dose) by Application (2019-2024)
 Table 69. Global Anti-VEGF Intravitreal Drugs Price (US$/Dose) by Application (2025-2030)
 Table 70. Roche Company Information
 Table 71. Roche Description and Business Overview
 Table 72. Roche Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 73. Roche Anti-VEGF Intravitreal Drugs Product
 Table 74. Roche Recent Developments/Updates
 Table 75. Novartis Company Information
 Table 76. Novartis Description and Business Overview
 Table 77. Novartis Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 78. Novartis Anti-VEGF Intravitreal Drugs Product
 Table 79. Novartis Recent Developments/Updates
 Table 80. Biogen Company Information
 Table 81. Biogen Description and Business Overview
 Table 82. Biogen Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 83. Biogen Anti-VEGF Intravitreal Drugs Product
 Table 84. Biogen Recent Developments/Updates
 Table 85. Coherus BioSciences Company Information
 Table 86. Coherus BioSciences Description and Business Overview
 Table 87. Coherus BioSciences Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 88. Coherus BioSciences Anti-VEGF Intravitreal Drugs Product
 Table 89. Coherus BioSciences Recent Developments/Updates
 Table 90. Regeneron Pharmaceuticals Company Information
 Table 91. Regeneron Pharmaceuticals Description and Business Overview
 Table 92. Regeneron Pharmaceuticals Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 93. Regeneron Pharmaceuticals Anti-VEGF Intravitreal Drugs Product
 Table 94. Regeneron Pharmaceuticals Recent Developments/Updates
 Table 95. Samsung Bioepis Company Information
 Table 96. Samsung Bioepis Description and Business Overview
 Table 97. Samsung Bioepis Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 98. Samsung Bioepis Anti-VEGF Intravitreal Drugs Product
 Table 99. Samsung Bioepis Recent Developments/Updates
 Table 100. Biocon Biologics Company Information
 Table 101. Biocon Biologics Description and Business Overview
 Table 102. Biocon Biologics Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 103. Biocon Biologics Anti-VEGF Intravitreal Drugs Product
 Table 104. Biocon Biologics Recent Developments/Updates
 Table 105. Qilu Pharma Company Information
 Table 106. Qilu Pharma Description and Business Overview
 Table 107. Qilu Pharma Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 108. Qilu Pharma Anti-VEGF Intravitreal Drugs Product
 Table 109. Qilu Pharma Recent Developments/Updates
 Table 110. Chengdu Kanghong Pharmaceutical Company Information
 Table 111. Chengdu Kanghong Pharmaceutical Description and Business Overview
 Table 112. Chengdu Kanghong Pharmaceutical Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 113. Chengdu Kanghong Pharmaceutical Anti-VEGF Intravitreal Drugs Product
 Table 114. Chengdu Kanghong Pharmaceutical Recent Developments/Updates
 Table 115. Key Raw Materials Lists
 Table 116. Raw Materials Key Suppliers Lists
 Table 117. Anti-VEGF Intravitreal Drugs Distributors List
 Table 118. Anti-VEGF Intravitreal Drugs Customers List
 Table 119. Anti-VEGF Intravitreal Drugs Market Trends
 Table 120. Anti-VEGF Intravitreal Drugs Market Drivers
 Table 121. Anti-VEGF Intravitreal Drugs Market Challenges
 Table 122. Anti-VEGF Intravitreal Drugs Market Restraints
 Table 123. Research Programs/Design for This Report
 Table 124. Key Data Information from Secondary Sources
 Table 125. Key Data Information from Primary Sources
 Table 126. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Anti-VEGF Intravitreal Drugs
 Figure 2. Global Anti-VEGF Intravitreal Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)
 Figure 3. Global Anti-VEGF Intravitreal Drugs Market Share by Type: 2023 & 2030
 Figure 4. Ranibizumab Product Picture
 Figure 5. Aflibercept Product Picture
 Figure 6. Conbercept Product Picture
 Figure 7. Brolucizumab Product Picture
 Figure 8. Faricimab Product Picture
 Figure 9. Other Product Picture
 Figure 10. Global Anti-VEGF Intravitreal Drugs Market Value by Application (2024-2030) & (US$ Million)
 Figure 11. Global Anti-VEGF Intravitreal Drugs Market Share by Application: 2023 & 2030
 Figure 12. Age-related Macular Degeneration
 Figure 13. Diabetic Macular Edema
 Figure 14. Retinal Vein Occlusion
 Figure 15. Other
 Figure 16. Global Anti-VEGF Intravitreal Drugs Revenue, (US$ Million), 2019 VS 2023 VS 2030
 Figure 17. Global Anti-VEGF Intravitreal Drugs Market Size (2019-2030) & (US$ Million)
 Figure 18. Global Anti-VEGF Intravitreal Drugs Sales (2019-2030) & (K Dose)
 Figure 19. Global Anti-VEGF Intravitreal Drugs Average Price (US$/Dose) & (2019-2030)
 Figure 20. Anti-VEGF Intravitreal Drugs Report Years Considered
 Figure 21. Anti-VEGF Intravitreal Drugs Sales Share by Manufacturers in 2023
 Figure 22. Global Anti-VEGF Intravitreal Drugs Revenue Share by Manufacturers in 2023
 Figure 23. Global 5 and 10 Largest Anti-VEGF Intravitreal Drugs Players: Market Share by Revenue in Anti-VEGF Intravitreal Drugs in 2023
 Figure 24. Anti-VEGF Intravitreal Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
 Figure 25. Global Anti-VEGF Intravitreal Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Figure 26. North America Anti-VEGF Intravitreal Drugs Sales Market Share by Country (2019-2030)
 Figure 27. North America Anti-VEGF Intravitreal Drugs Revenue Market Share by Country (2019-2030)
 Figure 28. United States Anti-VEGF Intravitreal Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 29. Canada Anti-VEGF Intravitreal Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 30. Europe Anti-VEGF Intravitreal Drugs Sales Market Share by Country (2019-2030)
 Figure 31. Europe Anti-VEGF Intravitreal Drugs Revenue Market Share by Country (2019-2030)
 Figure 32. Germany Anti-VEGF Intravitreal Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 33. France Anti-VEGF Intravitreal Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 34. U.K. Anti-VEGF Intravitreal Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 35. Italy Anti-VEGF Intravitreal Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 36. Russia Anti-VEGF Intravitreal Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 37. Asia Pacific Anti-VEGF Intravitreal Drugs Sales Market Share by Region (2019-2030)
 Figure 38. Asia Pacific Anti-VEGF Intravitreal Drugs Revenue Market Share by Region (2019-2030)
 Figure 39. China Anti-VEGF Intravitreal Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 40. Japan Anti-VEGF Intravitreal Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 41. South Korea Anti-VEGF Intravitreal Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 42. India Anti-VEGF Intravitreal Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 43. Australia Anti-VEGF Intravitreal Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 44. China Taiwan Anti-VEGF Intravitreal Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 45. Southeast Asia Anti-VEGF Intravitreal Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 46. Latin America Anti-VEGF Intravitreal Drugs Sales Market Share by Country (2019-2030)
 Figure 47. Mexico Anti-VEGF Intravitreal Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 48. Brazil Anti-VEGF Intravitreal Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 49. Argentina Anti-VEGF Intravitreal Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 50. Colombia Anti-VEGF Intravitreal Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 51. Middle East and Africa Anti-VEGF Intravitreal Drugs Sales Market Share by Country (2019-2030)
 Figure 52. Middle East and Africa Anti-VEGF Intravitreal Drugs Revenue Market Share by Country (2019-2030)
 Figure 53. Turkey Anti-VEGF Intravitreal Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 54. Saudi Arabia Anti-VEGF Intravitreal Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 55. UAE Anti-VEGF Intravitreal Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 56. Global Sales Market Share of Anti-VEGF Intravitreal Drugs by Type (2019-2030)
 Figure 57. Global Revenue Market Share of Anti-VEGF Intravitreal Drugs by Type (2019-2030)
 Figure 58. Global Anti-VEGF Intravitreal Drugs Price (US$/Dose) by Type (2019-2030)
 Figure 59. Global Sales Market Share of Anti-VEGF Intravitreal Drugs by Application (2019-2030)
 Figure 60. Global Revenue Market Share of Anti-VEGF Intravitreal Drugs by Application (2019-2030)
 Figure 61. Global Anti-VEGF Intravitreal Drugs Price (US$/Dose) by Application (2019-2030)
 Figure 62. Anti-VEGF Intravitreal Drugs Value Chain
 Figure 63. Anti-VEGF Intravitreal Drugs Production Process
 Figure 64. Channels of Distribution (Direct Vs Distribution)
 Figure 65. Bottom-up and Top-down Approaches for This Report
 Figure 66. Data Triangulation
 Figure 67. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Leap India